A股午間公吿:萬馬股份擬杭州臨安設立高分子材料銷售公司
1.國科恒泰:公司擬為董事、監事及高級管理人員購買責任險。2.致遠新能:披露2023年年度報吿及2024年第一季度報吿的時間由4月17日延期至4月23日。目前公司生產經營一切正常。3.萬馬股份:公司子公司——浙江萬馬高分子材料集團有限公司擬在杭州臨安投資設立浙江萬馬高分子材料銷售有限公司,統籌高分子材料產品的國內銷售業務,新材料銷售公司註冊資本5000萬元。4.中科環保:中誠信國際對公司主體信用狀況進行了評級,確定公司主體信用評級結果為AA+,評級展望為穩定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.